Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Aldesleukin + IMA201|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Aldesleukin||Proleukin||IL-2||Aldesleukin (IL-2) is a cytokine that potentially modulates antitumor immune response (NCI Drug Dictionary).|
|IMA201||IMA 201|IMA- 201||IMA201 are engineered autologous T cells expressing a T-cell receptor specific to a cancer-germline peptide, which may lead to targeted anti-tumor activity (Journal of Clinical Oncology 36, no. 5_suppl).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03247309||Phase I||Aldesleukin + IMA201 Cyclophosphamide + Fludarabine||TCR-engineered T Cells in Solid Tumors With Emphasis on NSCLC and HNSCC (ACTengine) (ACTengine)||Recruiting|